PE Tech Report


Like this article?

Sign up to our free newsletter

Blackstone completes acquisition of Clarus

Blackstone has closed its previously announced acquisition of Clarus, a global life sciences investment firm. Going forward, the business will operate as Blackstone Life Sciences, while historical funds will retain the Clarus name.

Blackstone Life Sciences is a new private investment platform with capabilities to invest across the life-cycle of companies and products within the key life sciences sectors. The business will leverage Clarus’ significant domain expertise and record of success, and Blackstone’s investment experience, operating platform and global scale, to help advance breakthrough products to address unmet medical needs.
Blackstone Life Sciences fills a critical void in the industry, which is seeing unprecedented growth, but lacks the necessary funding to bring medicines and healthcare technologies to market. The business will retain and build on Clarus’ hands-on approach of leveraging its scientific and clinical development expertise in adapting to an ever-changing investment landscape. This includes a focus on funding growth-stage investments, often in partnership with major biopharmaceutical companies through R&D collaborations.
Clarus is led by a team of seasoned experts who have invested in more than 50 companies in the biopharmaceutical, medical device and diagnostic sectors across multiple disease areas.

Like this article? Sign up to our free newsletter